Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 434 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Vascular Disorders Clear all
Completed Phase 1Phase 2 Interventional

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

NCT06664502
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Interventions
EYE201
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 10, 2026, 5:45 PM EST
Terminated No phase listed Observational

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

NCT01717937
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions
Phase variance optical coherence tomography (PV-OCT)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Levodopa for Diabetic Retinopathy

NCT07444892
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 10, 2026, 5:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Nov 10, 2026, 5:45 PM EST
Active, not recruiting Phase 2 Interventional

4D-150 in Patients With Diabetic Macular Edema

NCT05930561
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
4D-150 IVT, Aflibercept IVT
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional

Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement

NCT03531294
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Aflibercept Injection
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Houston, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Nov 10, 2026, 5:45 PM EST
Completed No phase listed Observational

Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

NCT03078231
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Color fundus photography, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Nov 10, 2026, 5:45 PM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

NCT05063734
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level, Aflibercept
Drug
Lead sponsor
Oxurion
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Huntington Beach, California • Pasadena, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 3 Interventional Results available

Treatment for Completers of the Study B7A-MC-MBCM

NCT00266695
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ruboxistaurin
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Nov 10, 2026, 5:45 PM EST
Not listed Phase 4 Interventional

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

NCT01857544
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Nov 10, 2026, 5:45 PM EST
Terminated Phase 4 Interventional

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

NCT04563299
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Nov 10, 2026, 5:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

NCT03931317
View directory record Official record
Conditions
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions
Latanoprostene bunod 0.024% QD, Timolol maleate 0.5% BID
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

NCT00052013
View directory record Official record
Conditions
Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma
Interventions
PTK787/ZK 222584
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

NCT05409235
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
OTT166, Vehicle control
Drug
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
67
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 1Phase 2 Interventional Results available

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

NCT03981549
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy
Biological
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Nov 10, 2026, 5:45 PM EST
Completed Not applicable Interventional

Diabetes Visual Function Supplement Study

NCT01646047
View directory record Official record
Conditions
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions
multi-component nutritional supplement capsules, multi-component dietary supplement
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

NCT01476449
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Clearwater, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Nov 10, 2026, 5:45 PM EST
Terminated Phase 3 Interventional Results available

PROMINENT-Eye Ancillary Study (Protocol AD)

NCT03345901
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Pemafibrate, Placebo
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Phoenix, Arizona • Campbell, California • Glendale, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

NCT00295828
View directory record Official record
Conditions
Iris Neovascularization, Diabetic Retinopathy
Interventions
Pegaptanib Sodium Injection/Panretinal Photocoagulation, Panretinal Photocoagulation (PRP)
Other · Procedure
Lead sponsor
Hermann Eye Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional

Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations

NCT00831350
View directory record Official record
Conditions
Retinal Vein Occlusion, Posterior Vitreous Detachment
Interventions
Ranibizumab
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

NCT00612456
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Nov 10, 2026, 5:45 PM EST
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

NCT03126786
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
IVT aflibercept, Sham SC, SC CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Nov 10, 2026, 5:45 PM EST
Completed No phase listed Observational

Bedside Optical Retinal Assessment of Hypoxic Ischemic Encephalopathy in Infants

NCT03640494
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Duke University
Other
Eligibility
Up to 20 Days
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 10, 2026, 5:45 PM EST